Stcube KRX:052020KOSDAQ

에스티큐브 · Korean news coverage and regulatory filings, organized.

Articles, 24h6
Articles, 7 days6
DART filings, 7 days0
Articles tracked6since Sep 11

In Q2 2026, Stcube reported revenue of ₩1.5bn, up 60.7% year on year, and an operating loss of ₩6.1bn. Stcube (에스티큐브) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 6 articles. The most common catalyst was clinical & approvals (2).

Stcube quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩1.5bn+60.7%−₩6.1bn−₩5.5bn
Q1 2026₩1.4bn-24.6%−₩7.3bn−₩6.7bn
Q4 2025 derived₩2.7bn+6.9%−₩7.0bn−₩6.6bn
Q3 2025₩1.5bn-53.1%−₩5.8bn−₩5.2bn
Q2 2025₩935m-68.0%−₩5.5bn−₩5.4bn
Q1 2025₩1.8bn-30.6%−₩5.2bn−₩4.6bn
Q4 2024 derived₩2.6bn+112.8%−₩5.6bn−₩4.9bn
Q3 2024₩3.2bn+245.4%−₩6.3bn−₩6.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Stcube top stories 2 weeks, by number of outlets

  1. 1
    [WCLC] 에스티큐브, ‘넬마스토바트’ NSCLC 임상2상서 초기 효능 신호 확인
    1 outlets · 1 articlesFirst report Sep 15 10:20 더바이오Clinical trial
  2. 2
    에스티큐브 폐암 신약, 기존 면역항암제 한계 뚫었다…임상 2상 청신호
    1 outlets · 1 articlesFirst report Sep 15 09:28 스마트투데이Clinical trial
  3. 3
    에스티큐브 BTN1A1 타깃 '넬마스토바트', 도세탁셀 넘어설까
    1 outlets · 1 articlesFirst report Sep 15 06:21 청년의사
  4. 4
    에스티큐브 '넬마스토바트', 폐암 2상서 초기 반응 확인
    1 outlets · 1 articlesFirst report Sep 15 09:27 메디파나뉴스
  5. 5
    에스티큐브 "비소세포폐암 2상서 강력한 초기 효능 신호"
    1 outlets · 1 articlesFirst report Sep 15 09:32 머니투데이
  6. 6
    에스티큐브, '넬마스토바트' 폐암 2상 초기 ORR 26.1% 기록
    1 outlets · 1 articlesFirst report Sep 15 09:37 뉴스핌

Latest Stcube news Korean headlines